Continuing trastuzumab beyond disease progression

Outcomes analysis in patients with metastatic breast cancer

Giuseppe Cancello, Emilia Montagna, Diego D'Agostino, Mario Giuliano, Antonio Giordano, Giuseppe Di Lorenzo, Monica Plaitano, Sabino De Placido, Michele De Laurentiis

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Introduction: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy lines. We also compared survival of these patients with that of those who halted trastuzumab at first PD.Methods: We identified 101 patients treated between July 2000 and January 2007. Nineteen were still receiving the first-line trastuzumab-based treatment without evidence of PD and were not included in this analysis. Of the remaining 82 patients, 59 retained trastuzumab for one or more additional lines of chemotherapy after PD, according to our institution policy. Twenty-three patients who changed treating institution and stopped trastuzumab at first progression were used as a control group.Results: For patients retaining trastuzumab, the median follow-up was 39.6 months. Clinical outcomes showed the typical degradation between first and second lines of therapy which we would expect by halting trastuzumab at first progression. Response rates were 35% and 16% and median times to progression were 7.25 and 5.25 months for the first and second lines of trastuzumab therapy, respectively. The median overall survival (OS) rates were 70 months for patients who retained trastuzumab and 56 months for patients who halted the drug (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.51 to 1.18; P = 0.52). If we consider OS from the start of trastuzumab therapy, the figures are 53.9 and 34.8 months, respectively (HR 0.78, 95% CI 0.58 to 1.32; P = 0.2).Conclusion: A nonstatistically significant trend of improved survival for patients retaining trastuzumab is observed. This is in line with most retrospective analyses and recent randomized data. Retaining trastuzumab after progression is a reasonable option, but further randomized data are warranted to better define its role in comparison with other available options.

Original languageEnglish
Article numberR60
JournalBreast Cancer Research
Volume10
Issue number4
DOIs
Publication statusPublished - Jul 16 2008

Fingerprint

Disease Progression
Breast Neoplasms
Survival
Trastuzumab
Confidence Intervals
Drug Therapy
Therapeutics
Survival Rate
Control Groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Continuing trastuzumab beyond disease progression : Outcomes analysis in patients with metastatic breast cancer. / Cancello, Giuseppe; Montagna, Emilia; D'Agostino, Diego; Giuliano, Mario; Giordano, Antonio; Di Lorenzo, Giuseppe; Plaitano, Monica; De Placido, Sabino; De Laurentiis, Michele.

In: Breast Cancer Research, Vol. 10, No. 4, R60, 16.07.2008.

Research output: Contribution to journalArticle

Cancello, Giuseppe ; Montagna, Emilia ; D'Agostino, Diego ; Giuliano, Mario ; Giordano, Antonio ; Di Lorenzo, Giuseppe ; Plaitano, Monica ; De Placido, Sabino ; De Laurentiis, Michele. / Continuing trastuzumab beyond disease progression : Outcomes analysis in patients with metastatic breast cancer. In: Breast Cancer Research. 2008 ; Vol. 10, No. 4.
@article{03be3e8781574aaaaef3f01779fe4420,
title = "Continuing trastuzumab beyond disease progression: Outcomes analysis in patients with metastatic breast cancer",
abstract = "Introduction: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy lines. We also compared survival of these patients with that of those who halted trastuzumab at first PD.Methods: We identified 101 patients treated between July 2000 and January 2007. Nineteen were still receiving the first-line trastuzumab-based treatment without evidence of PD and were not included in this analysis. Of the remaining 82 patients, 59 retained trastuzumab for one or more additional lines of chemotherapy after PD, according to our institution policy. Twenty-three patients who changed treating institution and stopped trastuzumab at first progression were used as a control group.Results: For patients retaining trastuzumab, the median follow-up was 39.6 months. Clinical outcomes showed the typical degradation between first and second lines of therapy which we would expect by halting trastuzumab at first progression. Response rates were 35{\%} and 16{\%} and median times to progression were 7.25 and 5.25 months for the first and second lines of trastuzumab therapy, respectively. The median overall survival (OS) rates were 70 months for patients who retained trastuzumab and 56 months for patients who halted the drug (hazard ratio [HR] 0.87, 95{\%} confidence interval [CI] 0.51 to 1.18; P = 0.52). If we consider OS from the start of trastuzumab therapy, the figures are 53.9 and 34.8 months, respectively (HR 0.78, 95{\%} CI 0.58 to 1.32; P = 0.2).Conclusion: A nonstatistically significant trend of improved survival for patients retaining trastuzumab is observed. This is in line with most retrospective analyses and recent randomized data. Retaining trastuzumab after progression is a reasonable option, but further randomized data are warranted to better define its role in comparison with other available options.",
author = "Giuseppe Cancello and Emilia Montagna and Diego D'Agostino and Mario Giuliano and Antonio Giordano and {Di Lorenzo}, Giuseppe and Monica Plaitano and {De Placido}, Sabino and {De Laurentiis}, Michele",
year = "2008",
month = "7",
day = "16",
doi = "10.1186/bcr2119",
language = "English",
volume = "10",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "4",

}

TY - JOUR

T1 - Continuing trastuzumab beyond disease progression

T2 - Outcomes analysis in patients with metastatic breast cancer

AU - Cancello, Giuseppe

AU - Montagna, Emilia

AU - D'Agostino, Diego

AU - Giuliano, Mario

AU - Giordano, Antonio

AU - Di Lorenzo, Giuseppe

AU - Plaitano, Monica

AU - De Placido, Sabino

AU - De Laurentiis, Michele

PY - 2008/7/16

Y1 - 2008/7/16

N2 - Introduction: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy lines. We also compared survival of these patients with that of those who halted trastuzumab at first PD.Methods: We identified 101 patients treated between July 2000 and January 2007. Nineteen were still receiving the first-line trastuzumab-based treatment without evidence of PD and were not included in this analysis. Of the remaining 82 patients, 59 retained trastuzumab for one or more additional lines of chemotherapy after PD, according to our institution policy. Twenty-three patients who changed treating institution and stopped trastuzumab at first progression were used as a control group.Results: For patients retaining trastuzumab, the median follow-up was 39.6 months. Clinical outcomes showed the typical degradation between first and second lines of therapy which we would expect by halting trastuzumab at first progression. Response rates were 35% and 16% and median times to progression were 7.25 and 5.25 months for the first and second lines of trastuzumab therapy, respectively. The median overall survival (OS) rates were 70 months for patients who retained trastuzumab and 56 months for patients who halted the drug (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.51 to 1.18; P = 0.52). If we consider OS from the start of trastuzumab therapy, the figures are 53.9 and 34.8 months, respectively (HR 0.78, 95% CI 0.58 to 1.32; P = 0.2).Conclusion: A nonstatistically significant trend of improved survival for patients retaining trastuzumab is observed. This is in line with most retrospective analyses and recent randomized data. Retaining trastuzumab after progression is a reasonable option, but further randomized data are warranted to better define its role in comparison with other available options.

AB - Introduction: We performed a retrospective analysis of HER2-overexpressing metastatic breast cancer patients to describe clinical outcomes of those who, despite progression of the disease (PD), maintained trastuzumab for multiple chemotherapy lines. We also compared survival of these patients with that of those who halted trastuzumab at first PD.Methods: We identified 101 patients treated between July 2000 and January 2007. Nineteen were still receiving the first-line trastuzumab-based treatment without evidence of PD and were not included in this analysis. Of the remaining 82 patients, 59 retained trastuzumab for one or more additional lines of chemotherapy after PD, according to our institution policy. Twenty-three patients who changed treating institution and stopped trastuzumab at first progression were used as a control group.Results: For patients retaining trastuzumab, the median follow-up was 39.6 months. Clinical outcomes showed the typical degradation between first and second lines of therapy which we would expect by halting trastuzumab at first progression. Response rates were 35% and 16% and median times to progression were 7.25 and 5.25 months for the first and second lines of trastuzumab therapy, respectively. The median overall survival (OS) rates were 70 months for patients who retained trastuzumab and 56 months for patients who halted the drug (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.51 to 1.18; P = 0.52). If we consider OS from the start of trastuzumab therapy, the figures are 53.9 and 34.8 months, respectively (HR 0.78, 95% CI 0.58 to 1.32; P = 0.2).Conclusion: A nonstatistically significant trend of improved survival for patients retaining trastuzumab is observed. This is in line with most retrospective analyses and recent randomized data. Retaining trastuzumab after progression is a reasonable option, but further randomized data are warranted to better define its role in comparison with other available options.

UR - http://www.scopus.com/inward/record.url?scp=65849322821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65849322821&partnerID=8YFLogxK

U2 - 10.1186/bcr2119

DO - 10.1186/bcr2119

M3 - Article

VL - 10

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 4

M1 - R60

ER -